New prospects for the drug treatment of generalized anxiety disorder - A systematic review

Current Drug Therapy

Volumn 5, Issue 2, 2010, Pages 86-94

  Glue, Paul ^a   Loan, Alistair ^a   Gale, Chris ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Beta 3 adrenoceptor agonists; Generalized anxiety disorder; glutamate receptor agonists; mitochondrial transporter protein ligands; Serotonin 1A partial agonists; Serotonin 2A 2C antagonists; Subtype selective benzodiazepine positive allosteric modulators

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; AGOMELATINE; ALPRAZOLAM; ANXIOLYTIC AGENT; BUSPIRONE; DERAMCICLANE FUMARATE; DIAZEPAM; EGLUMETAD; EMAPUNIL; ESZOPICLONE; GABOXADOL; GEPIRONE; HYDROXYZINE; IMIPRAMINE; LUAA 21004; MIRTAZAPINE; MK 0343; MK 0777; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; NEFAZODONE; OLANZAPINE; PERPHENAZINE; PLACEBO; PREGABALIN; QUETIAPINE; RILUZOLE; TIAGABINE; TRAZODONE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

DIZZINESS; DOSE RESPONSE; DRUG TREATMENT FAILURE; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 77951540408     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488510791065120     Document Type: Review

References (86)

1. th ed. 1994.
2. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006; 368: 2156-2166
3. Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 737-752
4. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001; 62 (Suppl 11): 22-27
5. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 141-150
6. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864-872
7. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr 2005; 27: 18-24.
8. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; 2: CD003592.
9. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 3: CD006115.
10. Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donohue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, openlabel study. Clin Ther 2008; 30: 1658-1666
11. Rickels K, Mathew S, Banov MD, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28: 235-239
12. Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997; 58: 30-38
13. Moore N, Bang-Andersen B, Brennum L, et al. Lu AA21004: a novel potential treatment for mood disorders. Eur Neuropsychopharmacol 2008; 18 (supplement 4): S321.
14. Freeman AM, Westphal JR, Norris GT, et al. Efficacy of ondansetron in the treatment of generalized anxiety disorder. Depress Anxiety 1997; 5: 140-141
15. Lecrubier Y, Puech AJ, Azcona A, Bailey PE, Lataste X. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1993; 112: 129-133
16. Artigas F, Dragheim M, Loft H, Perez V, Alvarez E. First double-blind randomized placebo-controlled acive referenced study of LuAA21004 in patients with major depressive disorder. Am Psychiat Assoc Annual Meeting abstracts, 2009; NR4-024.
17. Available at: http://www.lundbeck.com/investor/releases/Release Details/Release-1320878-EN.asp. [Accessed 23/11/09].
18. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884-895
19. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005; 19: 483-487
20. Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996; 32: 671-676
21. Naukkarinen H, Raassina R, Penttinen J, et al. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. Eur Neuropsychopharmacol 2005; 15: 617-623
22. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561-566
23. Stemmelin J, Cohen C, Terranova JP, et al. Stimulation of the beta 3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008; 33: 574-587
24. Griebel G, Sanger D. The mouse defense test battery: an experimental model of different emotional states. In: Haug M, Whalen RE, (Eds). Animal models of human emotion and cognition. Am Psychol Association: Washington, DC 1999; pp. 75-85.
25. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders - a review. J Clin Psychiatry 2006; 67: 1327-1340
26. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986; 47: 170-174
27. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2009; 20: 1-16.
28. A Multicenter, Randomized, Double-blind, Parallel-Group. Placebo controlled, active-controlled study of the efficacy and safety of sustained release quetiapine fumarate compared with placebo in the treatment of Generalized Anxiety Disorder (Gold Study). Study code D1448C00010; Available at: http://www.astrazenecaclinicaltrials. com/clinicaltrials/seroquel/ [Accessed: 24/11/09].
29. An 8-week, multicentre, randomised, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of quetiapine fumarate 50, 150, and 300 mg/day compared with placebo in the treatment of Generalised Anxiety Disorder (Titanium Study). Study Code D1448C00009; Available at: http://www.astrazenecaclinicaltrials. com/clinicaltrials/seroquel/ [Accessed: 24/11/09].
30. A Multi-Center, Double-Blind, Randomized, Parallel-Group. Placebo-controlled phase iii study of the efficacy and safety of quetiapine fumarate extended-release as monotherapy in the treatment of elderly patients with Generalized Anxiety Disorder (Chromium Study). Study Code D1448C00015; Avialable at: http:// www.astrazenecaclinicaltrials.com/clinicaltrials/seroquel/ [Accessed: 24, Nov, 2009].
31. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28: 519-526
32. Hoehn-Saric R. Effects of THIP on chronic anxiety. Psychopharmacology 1983; 80: 338-341
33. Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005; 66: 1401-1408
34. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64: 1245-1249
35. Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008; 28: 308-316
36. Atack JR. GABA-A receptor subtype-selective efficacy: TPA023, an α2/α3 selective non-sedating anxiolytic and α5IA, an α5 selective cognition enhancer. CNS Neurosci Ther 2008; 14: 25-35.
37. Atack J, Wong D, Fryer T, et al. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2- ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3- (2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine (TPA023) in rats, primates and man. J Pharmacol Exp Ther 2009 [Epub ahead of print].
38. de Haas SL, de Visser SJ, van der Post JP, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 2008; 22: 24-32.
39. de Haas SL, Franson KL, Schmitt JA, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol 2009; 23: 625-632
40. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Rev Neurosci 2005; 6: 565-575
41. Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav 2005; 82: 712-720
42. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325: 490-493
43. Bradwejn J, Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 2001; 234: 19-27.
44. Available at: (http://clinicaltrials.gov/ct2/show/NCT00616655? term=generalized+anxiety+disorder&rank=35). [Accessed: 3/12/09].
45. http://www.sepracor.com/products/sep225441.html. [Accessed: 3/12/09].
46. Erdman K, Stypinski D, Combs M, Witt P, Stiles M, Pollock S. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet. Pharmacotherapy 2007; 27: 1120-1124
47. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005; 179: 4-29.
48. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectr 2005; 10: 820-830
49. Fix AS. Pathological effects of MK-801 in the rat posterior cingulate/ retrosplenial cortex. Psychopharmacol Bull 1994; 30: 577-583
50. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-179
51. Mathew SJ, Amiel J, Coplan J, Fitterling H, Sackeim H, Gorman J. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005; 162: 2379-2381
52. Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008; 23: 109-114
53. Michelson D, Levine LR, Dellva MA, et al. Clinical studies with mGlu2/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacoly 2005; 49(S1): 84-257.
54. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacol 2008; 33: 1603-1610 (Pubitemid 351684700)
55. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45: 171-190
56. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280: 107-110
57. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105: 133-141
58. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771-782
59. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022-1030
60. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151-158
61. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-249
62. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533-540
63. Study A0081012. Clinicaltrials.gov identifier NCT00151450. [Accessed: 24/11/09].
64. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008; 193: 389-394
65. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998; 155: 992-993
66. Available at: http://clinicaltrials.gov/ct2/show/NCT00800280. [Accessed: 24/11/09].
67. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-1637
68. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder: a pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163-168
69. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252-1261
70. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-1334
71. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1-12
72. Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 2006; 50: 550-561
73. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 1996; 39: 703-707 (Pubitemid 26157605)
74. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00481325. [Accessed: 24/11/09].
75. Available at: http://media.pfizer.com/files/research/pipeline/2008- 0228/pipeline-2008-0228.pdf. [Accessed: 24/11/09].
76. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008; 89: 36-45.
77. Salomé N, Stemmelin J, Cohen C, Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 2006; 83: 533-539
78. Available at: http://clinicaltrials.gov/ct2/show/NCT00390650?term= Saredutant&rank=10. Accessed 24/11/09.
79. Available at: http://clinicaltrials.gov/ct2/show/NCT00390533? term=Saredutant&rank=11. [Accessed: 24/11/09].
80. Available at: http://clinicaltrials.gov/ct2/show?term= Saredutant&rank=13. [Accessed: 24/11/09].
81. Available at: http://www.sanofi-aventis.com/binaries/Lettre18-FR-Web-acc- tcm29-25341.pdf. [Accessed: 24/11/09].
82. van Steveninck AL, Gieschke R, Schoemaker RC, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 1996; 41: 565-573
83. Baldwin DS, Nair RV. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother 2005; 5: 443-449
84. Nutt D, Argyropoulos S, Hood S, Potokar J. Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol 2006; 16 (Suppl 2): S109-18.
85. Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr 2008; 13: 415-422
86. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - A metaanalysis. J Affect Disord 2009 [Epub ahead of print].